The manufacturer of Calquence is AstraZeneca [1][2].
What is Calquence used to treat?
Calquence (acalabrutinib) is a medication used to treat certain types of non-Hodgkin lymphoma (NHL). Specifically, it is indicated for adults with mantle cell lymphoma (MCL) who have received at least one prior therapy, and for adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) [3].
How does Calquence work?
Calquence is a targeted therapy that inhibits Bruton's tyrosine kinase (BTK), a protein crucial for the growth and survival of certain cancer cells, particularly B-cells. By blocking BTK, acalabrutinib interferes with signaling pathways that promote cancer cell proliferation and survival [3].
When did Calquence receive FDA approval?
The U.S. Food and Drug Administration (FDA) approved Calquence for MCL in January 2019 and for CLL/SLL in November 2019 [3].
What is the patent status of Calquence?
Drug patents for medications like Calquence are tracked by resources that monitor intellectual property. Information regarding patent expiry and potential challenges can be found on sites like DrugPatentWatch.com [4].
What are the common side effects of Calquence?
Common side effects reported with Calquence include diarrhea, fatigue, muscle aches, bruising, headache, and abdominal pain [3]. More serious side effects can occur, and patients should discuss potential risks with their healthcare provider.
How does Calquence compare to other lymphoma treatments?
Calquence is one of several treatment options for MCL, CLL, and SLL. Other therapies may include chemotherapy, immunotherapy, and other targeted agents. Treatment decisions are individualized based on the specific type and stage of lymphoma, as well as the patient's overall health [3].
Can generic versions of Calquence be made?
Generic versions, or biosimilars, of a drug can typically only be manufactured and marketed after the relevant patents expire and regulatory hurdles are cleared. The timeline for generic availability depends on patent protections [4].
Who manufactures Calquence globally?
AstraZeneca is the global manufacturer of Calquence. The drug is marketed under the brand name Calquence in the United States and various other countries [1][2].
What is the dosage and administration of Calquence?
Calquence is typically taken orally, usually twice daily, with or without food. The exact dosage and duration of treatment are determined by a healthcare professional based on the patient's condition [3].
What clinical trials have been conducted for Calquence?
Clinical trials for Calquence have evaluated its efficacy and safety in various patient populations with MCL, CLL, and SLL. Key trials include those that led to its FDA approvals, such as the ELEVATE-TN and ASCEND studies [3].
What are the patient concerns regarding Calquence?
Patients may have concerns about managing side effects, the long-term effectiveness of the treatment, and the cost of medication. Open communication with the healthcare team is essential for addressing these concerns [3].
What is the typical cost of Calquence?
The cost of prescription medications can vary significantly based on insurance coverage, pharmacy, and geographic location. Information on the price of Calquence is best obtained from pharmacies or through patient assistance programs.
---
Sources:
[1] https://www.astrazeneca.com/
[2] https://www.calquence.com/
[3] https://www.fda.gov/drugs/drug-approvals-and-databases/drug-approvals-and-closures
[4] https://drugpatentwatch.com/